Latest Headlines

Latest Headlines

Japan's Otsuka sues U.S. FDA over Abilify in unique focus on exclusivity rules

Japan's Otsuka Pharmaceuticals accused the U.S. FDA in a unique court suit of manipulating its regulatory procedures to kill off its 7-year exclusivity to market Abilify (aripiprazole) for treating Tourette syndrome in children.

India's Cadila Healthcare buys full control of Bharat Serums and Vaccines

India's Cadila Healthcare said it has bought out the shares of Bharat Serums and Vaccines to gain total control of their 10-year-old joint venture, Zydus BSV Pharma, and make it a wholly owned subsidiary.

Jaguar Animal Health eyes a second run at IPO

Stymied by a soft market response last year, Jaguar Animal Health is planning a second run at going public with hopes of raising $22 million, the company said in a new filing.

Gelesis gets $22M to advance stomach-filling hydrogel capsules to treat obesity

Gelesis has raised $22 million to support an ongoing 6-month trial of its first-generation weight loss capsule, Gelesis100. The company recently started the study to assess its impact on body weight and glycemic control. This data could be sufficient to gain a CE mark, the company expects.

Medtronic, Novartis back implantable beta cell diabetes device in $44M Series A, partnership

Semma Therapeutics aims to provide beta cells--the pancreatic cells that produce insulin--to patients with Type 1 diabetes. If the startup can get beyond early research, an implantable device that creates insulin via these stem cell-derived beta cells could replace daily insulin injections and transform patient care.

Are jeans and cash the biotech success formula for Asia?

If there is a formula for how to be creative in the biotech industry in Asia, it probably doesn't include ingredients like getting the dress code relaxed and walls of cash as far as the eye can see for basic research.

Ranbaxy set to disappear from Indian stock exchanges

In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.

Becton Dickinson plans respiratory asset sale in wake of CareFusion merger

Becton Dickinson is reviewing its assets now that the $12.4 billion CareFusion deal closed last week. The $30 billion medical products and diagnostics company is expected to sell the respiratory device business that was formerly part of CareFusion, Bloomberg reports.

Startup raising Series A to launch interactive, holographic surgical imaging software

Startup EchoPixel is taking volumetric images resulting from procedures such as MRIs, CT scans or breast tomosynthesis, and creating a holographic image that is interactive and can be viewed in real time during surgery.

UPDATED: Sun winds up Ranbaxy deal

Sun Pharmaceuticals and Ranbaxy Laboratories have jumped the final hurdle in their merger with government approval of a sale of 7 of their branded drugs to fellow India drugmaker Emcure Pharmaceuticals.